![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 26, 2020 12:27:21 AM
Those thoughts are exactly what I was referring to when I stated this within that BRTXQ post below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159101361
...if all of a sudden stem cells become not as popular and not marketable with millions of people that currently justify the huge demand out there that exists, then they would issue those 300 Billion shares and get their $30 Million back out of the market. It would be carried out as a worst case scenario price of .0001 if such were to happen. ...
I think I'll add a little more clarity to that thought. First though, I think it is important to note that I think this is their way of subliminally telling us that BRTXQ is going to have up to $30 Million in funding.
With 300 Billion shares at .0001 equating to $30,000,000 in funding, that is very obvious that such would be an extreme worst case scenario of which is really not imaginable in my opinion. Let's consider that their stem cell treatment is every bit as good as what BRTXQ and Auctus believes. Then I would suspect that the demand would be even greater than the demand that already exists out there for the stem cell treatment that BRTXQ offers. Then this would mean that we would see substantial price increases that would warrant the better side of the stair step of funding prices that I will show below in a pattern from a worst case scenario of .0001 per share for raising the funds to some much better scenarios up to $1.00 per share just to get an idea for why the 300 Billion shares will never hit the market and is really not imaginable:
$30,000,000 Funding ÷ .0001 per share = 300,000,000,000 shares
$30,000,000 Funding ÷ .001 per share = 30,000,000,000 shares
$30,000,000 Funding ÷ .01 per share = 3,000,000,000 shares
$30,000,000 Funding ÷ .10 per share = 300,000,000 shares
$30,000,000 Funding ÷ $1.00 per share = 30,000,000 shares
So just to make sure everyone understands, the above is the amount of shares that would be used to raise the up to $30 Million in funding with 300 Billion shares sold at .0001 per share as a worst case scenario to selling only 30,000,000 shares sold at $1.00 per share. As you can see, even if it's not logical for some to believe that BRTXQ could hit the $1.00 per share mark, then it should be logical to believe that it is very capable of hitting the .10 per share price range with volume which would warrant BRTXQ only selling 300,000,000 shares to raise the $30,000,000 in funding for the advancement of their FDA Approved Phase 2 Stem Cell Treatment. Their Clinical Trials could begin immediately after emerging from bankruptcy which would be fairly soon in my opinion.
A lot of this is going to come down to what one chooses to believe for having confidence in BRTXQ and Auctus. I personally have the utmost confidence in them both. Again, in my opinion, those 300 Billion shares will never get issued and are placed there as collateral as a protection mechanism for Auctus. No way they get sold into the market. Both BRTXQ and Auctus have too much skin in the game and no way will they make a mockery of themselves by doing such. Even at these current prices, they would need to sell under 2 Billion shares to raise the up $30 Million.
Also, this is a Joint Reorganization Plan for BRTXQ to emerge out of bankruptcy. In my opinion, it means a lot that Auctus is their partner with the plan to put their name to it too. If they had not done so, then maybe I would wonder if some kind of huge dilutive plan behind the scene exists. But since Actus had made the decision to become a partner and be the other half of the joint plan with BRTXQ, no way they are doing all of this to have their name tarnished within the market. Too much have been done. Too much blood, sweat, and tears have been invested by the both.
I was suspecting all along that we would see some sort of confirmation of funding greater than the $3.5 Million to pay for their financials to get current and to get them through the year operationally. We have now seen this as they will have up to $30 Million. Now I suspect that we will see a major name get involved to carry them through the finish line. I could think of a few to name, but I think many already might have a few ideas.
In my opinion, BRTXQ could prove to be finally coming off of the Similac and beginning to graduate from crawling to walking. I'm expecting that we could see a much shorter time frame for when BRTXQ graduates to running. It might happen much sooner than what I believe some think. Patience have proven to be a virtue here with BRTXQ.
v/r
Sterling
Exit Strategy & Etiquette Thoughts for a Stock
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128822531
I never give investing advice; only my beliefs for risks in a stock.
Recent BRTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:11:03 PM
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/08/2024 08:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:47:26 PM
- BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine • GlobeNewswire Inc. • 07/23/2024 11:10:00 AM
- BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/27/2024 11:40:00 AM
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Biotech Catches Major Premarket Bid Following FDA Clearance • AllPennyStocks.com • 04/16/2024 02:25:00 PM
- BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment • GlobeNewswire Inc. • 04/16/2024 11:45:00 AM
- BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 04/08/2024 11:45:00 AM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM